Retroperitoneal Ligation of Uterine Artery in Total Laparoscopic Hysterectomy for Enlarged Uterus

Retroperitoneal Ligation of Uterine Artery in Total Laparoscopic Hysterectomy for Enlarged Uterus: A Randomized Controlled Trial

Status

Suspended

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03101098

Enrollment

Registered

2017-04-04

Start date

2017-04-10

Completion date

2020-03-01

Last updated

2019-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hysterectomy

Brief summary

This randomized trial is aimed to investigate the role of retroperitoneal TLH in enlarge uterus.

Detailed description

Laparoscopic hysterectomy is one of the most common gynecologic surgeries worldwide. Generally, in total laparoscopic hysterectomy (TLH), uterine arteries are coagulated or transected close to the uterus, alongside the cervix, like surgical technique of a conventional total abdominal hysterectomy. Recently, several studies showed that ligation of uterine artery where it originates from the internal iliac artery during TLH (so-called retroperitoneal TLH) is effective for reducing blood loss. However, the application of this technique to clinical practice have not been well investigated in terms of its efficacy and safety. Moreover, most of the previous studies on retroperitoneal TLH were small case series or retrospective comparative studies with conventional TLH. Therefore, the investigators conducted this randomized trial to investigate the role of retroperitoneal TLH in enlarge uterus.

Interventions

PROCEDURERetroperitoneal liagation of uterine artery

the site of ligation of uterine artery is the area that it originates from the internal iliac artery during TLH

PROCEDUREClassical ligation of uterine artery

the site of ligation of uterine artery is the area alongside the cervix

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender

FEMALE

Age

19 Years to 70 Years

Healthy volunteers

Inclusion criteria

* absence of pregnancy at the time of presentation * uterine volume between 12 and 18 weeks of gestation by pelvic examination * appropriate medical status for laparoscopic surgery (American Society of Anesthesiologists Physical Status classification 1 or 2)

Exclusion criteria

* any suggestion of malignant uterine or adnexal diseases * any major medical comorbidities or psychiatric illnesses, which could affect follow-up and/or compliance * an inability to understand and provide written informed consent.

Design outcomes

Primary

Measure	Time frame	Description
Operative blood loss	Operation day	Operative blood loss was calculated by the anesthesiology unit as the difference between the total amount of suction and irrigation plus the difference between the total gauze weight before and after surgery.

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026